In the last trading session, 1.16 million Mereo Biopharma Group Plc ADR (NASDAQ:MREO) shares changed hands as the company’s beta touched 0.97. With the company’s per share price at $4.17 changed hands at $0.06 or 1.46% during last session, the market valuation stood at $641.18M. MREO’s last price was a discount, traded about -20.38% off its 52-week high of $5.02. The share price had its 52-week low at $1.07, which suggests the last value was 74.34% up since then. When we look at Mereo Biopharma Group Plc ADR’s average trading volume, we note the 10-day average is 0.72 million shares, with the 3-month average coming to 895.28K.
Analysts gave the Mereo Biopharma Group Plc ADR (MREO) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.20. If we narrow down to specifics, the data shows that 0 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended MREO as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight. Mereo Biopharma Group Plc ADR’s EPS for the current quarter is expected to be -0.02.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Mereo Biopharma Group Plc ADR (NASDAQ:MREO) trade information
Instantly MREO was in green as seen at the end of in last trading. With action 2.96%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 80.52%, with the 5-day performance at 2.96% in the green. However, in the 30-day time frame, Mereo Biopharma Group Plc ADR (NASDAQ:MREO) is -11.09% down. Looking at the short shares, we see there were 4.54 million shares sold at short interest cover period of 5.01 days.
The consensus price target for the stock as assigned by Wall Street analysts is 7.5, meaning bulls need an upside of 44.4% from its current market value. According to analyst projections, MREO’s forecast low is 4 with 8 as the target high. To hit the forecast high, the stock’s price needs a -91.85% plunge from its current level, while the stock would need to tank 4.08% for it to hit the projected low.
Mereo Biopharma Group Plc ADR (MREO) estimates and forecasts
Year-over-year growth is forecast to reach 43.20% up from the last financial year.
5 analysts are of the opinion that Mereo Biopharma Group Plc ADR’s revenue for the current quarter will be 14.6M.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 41.78%. The 2024 estimates are for Mereo Biopharma Group Plc ADR earnings to increase by 15.00%.
MREO Dividends
Mereo Biopharma Group Plc ADR is expected to release its next quarterly earnings report in November.
Mereo Biopharma Group Plc ADR (NASDAQ:MREO)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 1.08% of Mereo Biopharma Group Plc ADR shares while 65.49% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 66.20%. There are 65.49% institutions holding the Mereo Biopharma Group Plc ADR stock share, with RUBRIC CAPITAL MANAGEMENT LP the top institutional holder. As of 2024-06-30, the company held 2.1859% of the shares, roughly 15.31 million MREO shares worth $55.11 million.
ADAGE CAPITAL PARTNERS GP, L.L.C. holds the second largest percentage of outstanding shares, with 1.6838% or 11.79 million shares worth $42.45 million as of 2024-06-30.
